Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Dae Ho Lee et al.|Journal of Clinical Oncology|2024Cited by 137
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancerChanghwan Sung, Sook Ryun Park, Jinhyeon An et al.|Nature Cancer|2023Cited by 46
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Giuseppe Gullo, Tae Min Kim et al.|Journal of Clinical Oncology|2024Cited by 37